Relief Therapeutics is a small Swiss biopharmaceutical company focused on rare diseases, currently pivoting toward rare dermatological disorders while monetizing its existing product portfolio through licensing and royalties. Relief's lead development asset is RLF-TD011, a sprayable hypochlorous acid solution targeting wound care in epidermolysis bullosa (EB), a rare genetic skin disorder causing chronic blistering and open wounds. RLF-TD011 has FDA Orphan Drug Designation for EB and is in early-stage development, with a 12-patient proof-of-concept trial completed and a Phase 2 trial planned. On the commercial side, Relief's primary marketed product is PKU GOLIKE, a medical food for phenylketonuria (PKU) patients who cannot metabolize phenylalanine and require amino acid supplementation. GOLIKE is differentiated by a proprietary coating technology that mimics natural protein absorption and improves palatability. Relief licensed U.S. commercialization rights for GOLIKE to Eton Pharmaceuticals, retaining manufacturing obligations and earning a royalty on net sales. Relief also earns a 10% royalty on U.S. net sales of OLPRUVA, an FDA-approved urea cycle disorder treatment commercialized by Zevra Therapeutics. Additional legacy royalties come from CAMBIA, SETOFILM, and VOLTADOL, though CAMBIA royalties have declined following generic entry. Relief operates asset-light, relying entirely on contract manufacturers and partnering or out-licensing products rather than self-commercializing.